Whytock, C.W. and Shelton, C.L. (2026) Omics and anaesthesia : pharmacogenomics, proteomics and metabolomics. Anaesthesia and Intensive Care Medicine. ISSN 1472-0299 (In Press)
![[thumbnail of Whytock_and_Shelton_Omics_and_Anaesthesia_Accepted_Version]](https://eprints.lancs.ac.uk/style/images/fileicons/text.png)
Whytock_and_Shelton_Omics_and_Anaesthesia_Accepted_Version.pdf - Accepted Version
Available under License Creative Commons Attribution.
Download (2MB)
Abstract
Variation in response to drugs used in anaesthesia is seen between individuals and it is well established that patients' genetics are a major influence. Our understanding of the role differences in the genome play, especially by identifying genetic polymorphisms of interest, is improving. This may lead to availability of precision anaesthesia, where drug choices and dosages are tailored to individuals’ genetic makeup. Furthermore analysis of the downstream products of gene transcription, in particular of proteins and metabolic products, may allow further treatment personalization. Despite an improved ability to test patients and an improved understanding of relevant genetic polymorphisms, a number of practical considerations remain before widespread precision anaesthesia is likely to become available. Nevertheless this point in time may be drawing closer. It is therefore important for anaesthesia practitioners to have a comprehensive understanding of the underlying science of pharmacogenomics, proteomics and metabolomics; as well as knowledge of important polymorphisms of interest with respect to anaesthetic drugs and their clinical implications.